NCT06094179View on ClinicalTrials.gov

Evaluate the Safety, Tolerability of BAT6026

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

October 15, 2025

Conditions
Dermatitis, Atopic
Interventions
DRUG

Monoclonal antibody BAT6026

300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

DRUG

sodium chloride injection

300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)

Trial Locations (1)

Unknown

RECRUITING

Jianzhong Zhang, Beijing

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY